 Eprax, an erythropoietin analogue, has been shown to be effective in reducing renal tubular damage caused by gentamicin. When administered in combination with gentamicin, it significantly decreased the severity of renal tubule injury. Additionally, when administered after gentamicin induced renal tubule injury, Eprax was able to reduce the damage caused by gentamicin. These findings suggest that Eprax may be a potential therapeutic agent for treating renal tubule injury caused by gentamicin or other nephrotoxic agents. This article was authored by Mahmoud Rafienko P.I., Hamid Nasri, Mehdi Nemepax and others.